L3VLUP
ProSign in

RVMD · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RVMDARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RVMD
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterRVMDARGX
Q3 20203 holders, $388m8 holders, $3.6bn
Q4 20204 holders, $451m7 holders, $4.1bn
Q1 20215 holders, $846m8 holders, $4.1bn
Q2 20215 holders, $325m9 holders, $4.6bn
Q3 20213 holders, $133m8 holders, $4.5bn
Q4 20213 holders, $174m9 holders, $5.3bn
Q1 20223 holders, $174m8 holders, $5.3bn
Q2 20223 holders, $189m13 holders, $6.5bn
Q3 20223 holders, $206m14 holders, $5.3bn
Q4 20223 holders, $263m13 holders, $5.5bn
Q1 20235 holders, $526m13 holders, $5.9bn
Q2 20237 holders, $685m18 holders, $6.6bn
Q3 20238 holders, $766m21 holders, $8.7bn
Q4 20238 holders, $1.0bn17 holders, $6.3bn
Q1 202410 holders, $1.3bn13 holders, $6.8bn
Q2 20249 holders, $1.6bn14 holders, $7.9bn
Q3 202410 holders, $1.9bn13 holders, $10.7bn
Q4 202411 holders, $2.2bn14 holders, $12.3bn
Q1 20257 holders, $1.7bn17 holders, $11.8bn
Q2 20258 holders, $1.7bn18 holders, $10.8bn
Q3 20257 holders, $2.2bn16 holders, $13.8bn
Q4 202518 holders, $4.3bn16 holders, $14.8bn
Q1 202615 holders, $4.8bn11 holders, $12.3bn
Q2 202617 holders, $10.3bn14 holders, $15.0bn
RVMD

Revolution Medicines Inc

Holders
18
Reported value
$4.3bn
Buyers
23
Sellers
9

Breadth +14 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
16
Reported value
$14.8bn
Buyers
14
Sellers
16

Breadth -2 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2025

Among the 25 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RVMD (9)

Baillie Gifford & Co, Brevan Howard Capital Management LP, D. E. Shaw & Co., Farallon Capital Management LLC, Holocene Advisors LP, Marshall Wace LLP, Verition Fund Management LLC, Voloridge Investment Management LLC, Winton Group Ltd

Only ARGX (7)

Acadian Asset Management LLC, AllianceBernstein LP, Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, Hudson Bay Capital Management LP, Invesco Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →